Federal Register / Vol. 76, No. 204 / Friday, October 21, 2011 / Notices 65537 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–358] 

Controlled Substances: Proposed 

Aggregate Production Quotas for 2012 

AGENCY: Drug Enforcement 

Administration (DEA), Department of 

Justice. 

ACTION: Notice with request for 

comment. 

SUMMARY: This notice proposes initial 

year 2012 aggregate production quotas 

for controlled substances in Schedules I 

and II of the Controlled Substances Act 

(CSA). 

DATES: Electronic comments must be 

submitted and written comments must 

be postmarked on or before November 

21, 2011. Commenters should be aware 

that the electronic Federal Docket 

Management System will not accept 

comments after midnight Eastern Time 

on the last day of the comment period. 

ADDRESSES: To ensure proper handling 

of comments, please reference ‘‘Docket 

No. DEA–358’’ on all electronic and 

written correspondence. DEA 

encourages that all comments be 

submitted electronically through http:// 

www.regulations.gov using the 

electronic comment form provided on 

that site. An electronic copy of this 

document is also available at the 

http://www.regulations.gov Web site for 

easy reference. Paper comments that 

duplicate the electronic submission are 

not necessary as all comments 

submitted to http://www.regulations.gov 

will be posted for public review and are 

part of the official docket record. 

Written comments submitted via regular 

or express mail should be sent to the 

Drug Enforcement Administration, 

Attention: DEA Federal Register 

Representative/OD, 8701 Morrissette 

Drive, Springfield, VA 22152. 

FOR FURTHER INFORMATION CONTACT: 

Rhea D. Moore, Office of Diversion 

Control, Drug Enforcement 

Administration, 8701 Morrissette Drive, 

Springfield, VA 22152, Telephone: (202) 

307–7165. 

SUPPLEMENTARY INFORMATION: 

Posting of Public Comments 

Please note that all comments 

received are considered part of the 

public record and made available for 

public inspection online at http:// 

www.regulations.gov and in the DEA’s 

public docket. Such information 

includes personal identifying 

information (such as your name, 

address, etc.) voluntarily submitted by 

the commenter. 

If you want to submit personal 

identifying information (such as your 

name, address, etc.) as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘PERSONAL IDENTIFYING 

INFORMATION’’ in the first paragraph 

of your comment. You must also place 

all the personal identifying information 

you do not want posted online or made 

available in the public docket in the first 

paragraph of your comment and identify 

what information you want redacted. 

If you want to submit confidential 

business information as part of your 

comment, but do not want it to be 

posted online or made available in the 

public docket, you must include the 

phrase ‘‘CONFIDENTIAL BUSINESS 

INFORMATION’’ in the first paragraph 

of your comment. You must also 

prominently identify confidential 

business information to be redacted 

within the comment. If a comment has 

so much confidential business 

information that it cannot be effectively 

redacted, all or part of that comment 

may not be posted online or made 

available in the public docket. 

Personal identifying information and 

confidential business information 

identified and located as set forth above 

will be redacted, and the comment, in 

redacted form, will be posted online and 

placed in the DEA’s public docket file. 

Please note that the Freedom of 

Information Act applies to all comments 

received. If you wish to inspect the 

agency’s public docket file in person by 

appointment, please see the FOR

FURTHER INFORMATION CONTACT

paragraph. 

Background 

Section 306 of the CSA (21 U.S.C. 

826) requires that the Attorney General 

establish aggregate production quotas 

for each basic class of controlled 

substance listed in Schedules I and II. 

This responsibility has been delegated 

to the Administrator of the DEA by 

28 CFR 0.100. 

The proposed year 2012 aggregate 

production quotas represent those 

quantities of Schedule I and II 

controlled substances that may be 

produced in the United States in 2012 

to provide adequate supplies of each 

substance for the estimated medical, 

scientific, research, and industrial needs 

of the United States, lawful export 

requirements, and the establishment 

and maintenance of reserve stocks. 

These quotas do not include imports of 

controlled substances for use in 

industrial processes. 

In determining the proposed 2012 

aggregate production quotas, the DEA 

has taken into account the criteria that 

DEA is required to consider in 

accordance with 21 U.S.C. 826(a) and 

21 CFR 1303.11. DEA proposes the 

aggregate production quotas for 2012 by 

considering (1) total net disposal of the 

class by all manufacturers during the 

current and two preceding years; (2) 

trends in the national rate of net 

disposal of the class; (3) total actual (or 

estimated) inventories of the class and 

of all substances manufactured from the 

class, and trends in inventory 

accumulation; (4) projected demand for 

such class as indicated by procurement 

quotas requested pursuant to 21 CFR 

1303.12; and (5) other factors affecting 

the medical, scientific, research, and 

industrial needs in the United States, 

lawful export requirements, and reserve 

stocks, as the Administrator finds 

relevant. Other factors DEA considered 

include product development 

requirements of both bulk and finished 

dosage form manufacturers, and other 

pertinent information. 

The Administrator, therefore, 

proposes that the year 2012 aggregate 

production quotas for the following 

Schedule I and II controlled substances, 

expressed in grams of anhydrous acid or 

base, be established as follows: 

Basic class—Schedule I 

Proposed 2012 

quotas 

(g) 

1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) ......................................................................................................... 45 

1-Butyl-3-(1-naphthoyl)indole (JWH-073) ...................................................................................................................................... 45 

1-Methyl-4-phenyl-4-propionoxypiperidine ..................................................................................................................................... 2 

1-Pentyl-3-(1-naphthoyl)indole (JWH-018) .................................................................................................................................... 45 

2,5-Dimethoxyamphetamine .......................................................................................................................................................... 2 

2,5-Dimethoxy-4-ethylamphetamine (DOET) ................................................................................................................................ 2 

2,5-Dimethoxy-4-n-propylthiophenethylamine ............................................................................................................................... 2 


sroberts on DSK5SPTVN1PROD with NOTICES
65538 Federal Register / Vol. 76, No. 204 / Friday, October 21, 2011 / Notices 

Basic class—Schedule I 

Proposed 2012 

quotas 

(g) 

3-Methylfentanyl ............................................................................................................................................................................. 2 

3-Methylthiofentanyl ....................................................................................................................................................................... 2 

3,4-Methylenedioxyamphetamine (MDA) ...................................................................................................................................... 22 

3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ....................................................................................................................... 15 

3,4-Methylenedioxymethamphetamine (MDMA) ........................................................................................................................... 22 

3,4,5-Trimethoxyamphetamine ...................................................................................................................................................... 2 

4-Bromo-2,5-dimethoxyamphetamine (DOB) ................................................................................................................................ 2 

4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ............................................................................................................................ 2 

4-Methoxyamphetamine ................................................................................................................................................................ 77 

4-Methylaminorex .......................................................................................................................................................................... 2 

4-Methyl-2,5-dimethoxyamphetamine (DOM) ................................................................................................................................ 2 

5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ................................................................................................... 68 

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ..................................................................................................... 53 

5-Methoxy-3,4-methylenedioxyamphetamine ................................................................................................................................ 2 

5-Methoxy-N,N-diisopropyltryptamine ............................................................................................................................................ 2 

Acetyl-alpha-methylfentanyl ........................................................................................................................................................... 2 

Acetyldihydrocodeine ..................................................................................................................................................................... 2 

Acetylmethadol .............................................................................................................................................................................. 2 

Allylprodine .................................................................................................................................................................................... 2 

Alphacetylmethadol ........................................................................................................................................................................ 2 

Alpha-ethyltryptamine .................................................................................................................................................................... 2 

Alphameprodine ............................................................................................................................................................................. 2 

Alphamethadol ............................................................................................................................................................................... 2 

Alpha-methylfentanyl ..................................................................................................................................................................... 2 

Alpha-methylthiofentanyl ................................................................................................................................................................ 2 

Alpha-methyltryptamine (AMT) ...................................................................................................................................................... 2 

Aminorex ........................................................................................................................................................................................ 2 

Benzylmorphine ............................................................................................................................................................................. 2 

Betacetylmethadol ......................................................................................................................................................................... 2 

Beta-hydroxy-3-methylfentanyl ...................................................................................................................................................... 2 

Beta-hydroxyfentanyl ..................................................................................................................................................................... 2 

Betameprodine ............................................................................................................................................................................... 2 

Betamethadol ................................................................................................................................................................................. 2 

Betaprodine .................................................................................................................................................................................... 2 

Bufotenine ...................................................................................................................................................................................... 3 

Cathinone ....................................................................................................................................................................................... 4 

Codeine-N-oxide ............................................................................................................................................................................ 602 

Diethyltryptamine ........................................................................................................................................................................... 2 

Difenoxin ........................................................................................................................................................................................ 50 

Dihydromorphine ............................................................................................................................................................................ 3,608,000 

Dimethyltryptamine ........................................................................................................................................................................ 7 

Gamma-hydroxybutyric acid .......................................................................................................................................................... 29,000,000 

Heroin ............................................................................................................................................................................................ 20 

Hydromorphinol .............................................................................................................................................................................. 2 

Hydroxypethidine ........................................................................................................................................................................... 2 

Ibogaine ......................................................................................................................................................................................... 5 

Lysergic acid diethylamide (LSD) .................................................................................................................................................. 16 

Marihuana ...................................................................................................................................................................................... 21,000 

Mescaline ....................................................................................................................................................................................... 5 

Methaqualone ................................................................................................................................................................................ 10 

Methcathinone ............................................................................................................................................................................... 4 

Methyldihydromorphine .................................................................................................................................................................. 2 

Morphine-N-oxide .......................................................................................................................................................................... 605 

N-Benzylpiperazine ........................................................................................................................................................................ 2 

N,N-Dimethylamphetamine ............................................................................................................................................................ 2 

N-Ethylamphetamine ..................................................................................................................................................................... 2 

N-Hydroxy-3,4-methylenedioxyamphetamine ................................................................................................................................ 2 

Noracymethadol ............................................................................................................................................................................. 2 

Norlevorphanol ............................................................................................................................................................................... 52 

Normethadone ............................................................................................................................................................................... 2 

Normorphine .................................................................................................................................................................................. 18 

Para-fluorofentanyl ......................................................................................................................................................................... 2 

Phenomorphan .............................................................................................................................................................................. 2 

Pholcodine ..................................................................................................................................................................................... 2 

Psilocybin ....................................................................................................................................................................................... 2 

Psilocyn .......................................................................................................................................................................................... 2 

Tetrahydrocannabinols .................................................................................................................................................................. 393,000 

Thiofentanyl ................................................................................................................................................................................... 2 

Tilidine ............................................................................................................................................................................................ 10 

Trimeperidine ................................................................................................................................................................................. 2 


sroberts on DSK5SPTVN1PROD with NOTICES
Federal Register / Vol. 76, No. 204 / Friday, October 21, 2011 / Notices 65539 

Basic class—Schedule II 

Proposed 2012 

quotas 

(g) 

1-Phenylcyclohexylamine .............................................................................................................................................................. 2 

1-Piperdinocyclohexanecarbonitrile ............................................................................................................................................... 2 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ................................................................................................................................... 1,800,000 

Alfentanil ........................................................................................................................................................................................ 11,600 

Alphaprodine .................................................................................................................................................................................. 2 

Amobarbital .................................................................................................................................................................................... 40,007 

Amphetamine (for conversion) ...................................................................................................................................................... 8,500,000 

Amphetamine (for sale) ................................................................................................................................................................. 25,300,000 

Cocaine .......................................................................................................................................................................................... 216,000 

Codeine (for conversion) ............................................................................................................................................................... 65,000,000 

Codeine (for sale) .......................................................................................................................................................................... 39,605,000 

Dextropropoxyphene ...................................................................................................................................................................... 7 

Dihydrocodeine .............................................................................................................................................................................. 255,000 

Diphenoxylate ................................................................................................................................................................................ 500,000 

Ecgonine ........................................................................................................................................................................................ 83,000 

Ethylmorphine ................................................................................................................................................................................ 2 

Fentanyl ......................................................................................................................................................................................... 1,428,000 

Glutethimide ................................................................................................................................................................................... 2 

Hydrocodone (for sale) .................................................................................................................................................................. 59,000,000 

Hydromorphone ............................................................................................................................................................................. 3,455,000 

Isomethadone ................................................................................................................................................................................ 4 

Levo-alphacetylmethadol (LAAM) .................................................................................................................................................. 3 

Levomethorphan ............................................................................................................................................................................ 5 

Levorphanol ................................................................................................................................................................................... 3,600 

Lisdexamfetamine .......................................................................................................................................................................... 10,400,000 

Meperidine ..................................................................................................................................................................................... 5,200,000 

Meperidine Intermediate—A .......................................................................................................................................................... 3 

Meperidine Intermediate—B .......................................................................................................................................................... 7 

Meperidine Intermediate—C .......................................................................................................................................................... 3 

Metazocine ..................................................................................................................................................................................... 5 

Methadone (for sale) ..................................................................................................................................................................... 20,000,000 

Methadone Intermediate ................................................................................................................................................................ 26,000,000 

Methamphetamine ......................................................................................................................................................................... 3,130,000 

[750,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,331,000 grams for methamphetamine mostly 

for conversion to a schedule III product; and 49,000 grams for methamphetamine (for sale)] 

Methylphenidate ............................................................................................................................................................................. 56,000,000 

Morphine (for conversion) .............................................................................................................................................................. 83,000,000 

Morphine (for sale) ........................................................................................................................................................................ 39,000,000 

Nabilone ......................................................................................................................................................................................... 10,502 

Noroxymorphone (for conversion) ................................................................................................................................................. 7,200,000 

Noroxymorphone (for sale) ............................................................................................................................................................ 401,000 

Opium (powder) ............................................................................................................................................................................. 63,000 

Opium (tincture) ............................................................................................................................................................................. 1,000,000 

Oripavine ........................................................................................................................................................................................ 9,800,000 

Oxycodone (for conversion) .......................................................................................................................................................... 5,600,000 

Oxycodone (for sale) ..................................................................................................................................................................... 98,000,000 

Oxymorphone (for conversion) ...................................................................................................................................................... 12,800,000 

Oxymorphone (for sale) ................................................................................................................................................................. 5,500,000 

Pentobarbital .................................................................................................................................................................................. 31,000,000 

Phenazocine .................................................................................................................................................................................. 5 

Phencyclidine ................................................................................................................................................................................. 24 

Phenmetrazine ............................................................................................................................................................................... 2 

Phenylacetone ............................................................................................................................................................................... 8,000,000 

Racemethorphan ........................................................................................................................................................................... 2 

Remifentanil ................................................................................................................................................................................... 2,500 

Secobarbital ................................................................................................................................................................................... 336,002 

Sufentanil ....................................................................................................................................................................................... 5,000 

Tapentadol ..................................................................................................................................................................................... 243,000 

Thebaine ........................................................................................................................................................................................ 116,000,000 

The Administrator further proposes 

that aggregate production quotas for all 

other Schedule I and II controlled 

substances included in 21 CFR 1308.11 

and 1308.12 be established at zero. 

Pursuant to 21 CFR 1303.13, upon 

consideration of the relevant factors, the 

Administrator of the DEA may adjust 

the 2012 aggregate production quotas as 

needed. 

Comments 

Pursuant to 21 CFR 1303.11, any 

interested person may submit written 

comments on or objections to these 

proposed determinations. Based on 

comments received in response to this 

Notice, the Administrator may hold a 

public hearing on one or more issues 

raised. In the event the Administrator 

decides in her sole discretion to hold 


sroberts on DSK5SPTVN1PROD with NOTICES
65540 Federal Register / Vol. 76, No. 204 / Friday, October 21, 2011 / Notices 

such a hearing, the Administrator will 

publish a notice of any such hearing in 

the Federal Register. After 

consideration of any comments and 

after a hearing, if one is held, the 

Administrator will publish in the 

Federal Register a final order 

determining the 2012 aggregate 

production quota for the basic class of 

controlled substance. 

Dated: October 7, 2011. 

Michele M. Leonhart, 

Administrator. 

[FR Doc. 2011–27283 Filed 10–20–11; 8:45 am] 

BILLING CODE 4410–09–P 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[Notice: (11–101)] 

NASA Advisory Council; Audit, 

Finance, and Analysis Committee 

Meeting 

AGENCY: National Aeronautics and 

Space Administration. 

ACTION: Notice of meeting change of 

location. 

Reference: Federal Register/Vol. 76, 

No. 200, Monday, October 17, 2011 

(Notice 11–096, 64112). 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, Public 

Law 92–463, as amended, the National 

Aeronautics and Space Administration 

(NASA) announces that the meeting of 

the Audit, Finance and Analysis 

Committee of the NASA Advisory 

Council scheduled to be held at NASA 

Goddard Space Flight Center in 

Greenbelt, Maryland, on November 1–2, 

2011, has been moved to a new location. 

It will now be held as follows: NASA 

Headquarters, Room 8D48, 300 E Street, 

SW., Washington, DC 20546, Tuesday, 

November 1, 2011, 2:00–5:15 p.m. and 

Wednesday, November 2, 2011, 

9:00–9:55 a.m., Local Time. 

FOR FURTHER INFORMATION CONTACT: 

Ms. Charlene Williams, Office of the 

Chief Financial Officer, NASA 

Headquarters, Washington, DC 20546, 

Phone: 202–358–2183. 

SUPPLEMENTARY INFORMATION: The 

meeting will be open to the public up 

to the seating capacity of the room. 

Visitors will need to show a valid 

picture identification such as a driver’s 

license to enter the NASA Headquarters 

building (West Lobby—Visitor Control 

Center), and must state that they are 

attending the Audit, Finance, and 

Analysis Committee meeting in room 

8D48 before receiving an access badge. 

All non-U.S. citizens must fax a copy of 

their passport, and print or type their 

name, current address, citizenship, 

company affiliation (if applicable) to 

include address, telephone number, and 

their title, place of birth, date of birth, 

U.S. visa information to include type, 

number, and expiration date, U.S. Social 

Security Number (if applicable), and 

place and date of entry into the U.S., fax 

to Charlene Williams, Executive 

Secretary, Audit, Finance, and Analysis 

Committee, FAX (202) 358–4336, by no 

later than October 27, 2011. 

Dated: October 18, 2011. 

P. Diane Rausch, 

Advisory Committee Management Officer, 

National Aeronautics and Space 

Administration. 

[FR Doc. 2011–27329 Filed 10–20–11; 8:45 am] 

BILLING CODE 7510–13–P 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[Notice (11–099)] 

National Space-Based Positioning, 

Navigation, and Timing (PNT) Advisory 

Board; Meeting 

AGENCY: National Aeronautics and 

Space Administration (NASA). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act (Pub. 

L. 92–463, as amended), and the 

President’s 2004 U.S. Space-Based 

Positioning, Navigation, and Timing 

Policy, the National Aeronautics and 

Space Administration announces a 

meeting of the National Space-Based 

Positioning, Navigation, and Timing 

Advisory Board. 

DATES: Wednesday, November 9, 2011, 

9 a.m. to 5 p.m.; and Thursday, 

November 10, 2011, 9 a.m. to 1 p.m. 

ADDRESSES: The Crowne Plaza Old 

Town Alexandria, 901 North Fairfax, 

Washington Ballroom, Alexandria, VA 

22314. 

FOR FURTHER INFORMATION CONTACT: 

Mr. James J. Miller, Human Exploration 

and Operations Mission Directorate, 

National Aeronautics and Space 

Administration, Washington, DC 20546, 

(202) 358–4417. 

SUPPLEMENTARY INFORMATION: The 

meeting will be open to the public up 

to the seating capacity of the room. It is 

imperative that the meeting be held on 

these dates to accommodate the 

scheduling priorities of the key 

participants. Visitors will be requested 

to sign a visitor’s register. The agenda 

for the meeting includes the following 

topics: 

• Update on U.S. Space-Based 

Positioning, Navigation and Timing 

Policy and Global Positioning System 

(GPS) modernization. 

• Explore opportunities for enhancing 

the interoperability of GPS with other 

emerging international Global 

Navigation Satellite System 

constellation services. 

• Examine emerging trends and 

requirements for PNT services in U.S. 

and international arenas through PNT 

Board technical assessments. 

• Prioritize current and planned GPS 

capabilities and services while assessing 

future PNT architecture options. 

• Review GPS Standard Positioning 

Service Performance Standards and 

effects on ‘‘non-ICD compliant’’ 

receivers in the marketplace. 

• Address future challenges to PNT 

service providers and users such as 

protecting the emerging role of PNT in 

cyber networks, including the need for 

back-ups. 

• Identify and respond to the latest 

developments on radio frequency 

interference from proposed Mobile 

Satellite Service Ancillary Terrestrial 

Component operations. 

Dated: October 14, 2011. 

P. Diane Rausch, 

Advisory Committee Management Officer, 

National Aeronautics and Space 

Administration. 

[FR Doc. 2011–27256 Filed 10–20–11; 8:45 am] 

BILLING CODE 7510–13–P 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[Notice: (11–100)] 

NASA Advisory Council; Meeting 

AGENCY: National Aeronautics and 

Space Administration. 

ACTION: Notice of meeting cancellation. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, Public 

Law 92–463, as amended, the National 

Aeronautics and Space Administration 

announces that the meeting of the 

NASA Advisory Council scheduled to 

be held at NASA Goddard Space Flight 

Center in Greenbelt, Maryland, on 

November 3–4, 2011, has been 

postponed due to scheduling conflict. It 

will be rescheduled in the future. 

FOR FURTHER INFORMATION CONTACT: 

Ms. Marla King, NAC Administrative 

Officer, National Aeronautics and Space 

Administration, Washington, DC 20546, 

202/358–1148. 


sroberts on DSK5SPTVN1PROD with NOTICES